Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-48,385
Closed -$91.4K 12870
2025
Q4
$91.4K Buy
48,385
+7,869
+19% +$14.5K ﹤0.01% 11709
2025
Q3
$79.8K Buy
+40,516
New +$82.9K ﹤0.01% 11976
2024
Q2
Sell
-12,995
Closed -$36.6K 14139
2024
Q1
$36.6K Buy
+12,995
New +$40.5K ﹤0.01% 12484
2023
Q2
Sell
-12,805
Closed -$18.1K 14256
2023
Q1
$18.1K Buy
+12,805
New +$21.8K ﹤0.01% 13137
2022
Q1
Sell
-16,753
Closed -$134K 13461
2021
Q4
$134K Buy
+16,753
New +$172K ﹤0.01% 12407
2021
Q2
Sell
-22,371
Closed -$402K 13577
2021
Q1
$402K Buy
+22,371
New +$510K ﹤0.01% 10164

Other funds holding ADAG

Citadel Advisors's ADAG Position: Q1 2026 in Review

Citadel Advisors sold out of Adagene (ADAG) in Q1 2026, closing a stake of 48,385 shares — an estimated $91.4K sold.

Citadel Advisors first reported a position in ADAG in Q1 2021 and held it in 6 quarters. The position peaked at $402K in Q1 2021. 25 funds tracked by Wall St. Rank hold ADAG as of Q1 2026.

  • Citadel Advisors reported no remaining Adagene position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 48,385 Adagene shares in Q1 2026, an estimated $91.4K.
  • Citadel Advisors first reported a position in Adagene in Q1 2021 and held it in 6 quarters.
  • Citadel Advisors's Adagene position peaked at $402K in Q1 2021.
  • 25 funds tracked by Wall St. Rank held Adagene as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.